The first trial of gene therapy for PD proposed to deliver rAAV vectors expressing the two isoforms of the enzyme glutamic acid decarboxylase (GAD-65 and GAD-67), which synthesize the major inhibitory neurotransmitter, gamma aminobutyric acid (GABA) targeting the subthalamic nucleus (STN) [15]. Here, GAD1 is linked to Parkinson disease.